Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
36
FDA:29
NMPA:7
Drug Approvals
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- 国药准字HJ20171062
- Approval Date
- Feb 6, 2024
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- 国药准字HJ20150419
- Approval Date
- Feb 6, 2024
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- 国药准字HJ20150431
- Approval Date
- Feb 6, 2024
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- 国药准字J20140167
- Approval Date
- Jul 31, 2019
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- H20150431
- Approval Date
- May 22, 2019
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- H20171062
- Approval Date
- May 22, 2019
NMPA
Montelukast Sodium Oral Granules
- Product Name
- 顺尔宁
- Approval Number
- H20150419
- Approval Date
- May 22, 2019
NMPA
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)No trials found
News
Bio-Thera Solutions Initiates Phase 3 Trial for BAT8006 ADC in Platinum-Resistant Ovarian Cancer
Bio-Thera Solutions has dosed the first patient in a pivotal phase 3 trial for BAT8006, an antibody-drug conjugate targeting folate receptor α for platinum-resistant ovarian cancer treatment.